Alivus Life Sciences opened higher at ₹1,350.10, compared with its previous close of ₹1,345.20. During today's session, the stock has traded between ₹1,309.20 and ₹1,354.80, with an average traded price of ₹1,333.47. It is currently showing a sideways intraday trend.
An investment of ₹10,000 made 5 years ago in Alivus Life Sciences is now worth
₹ 20,147.00
giving a profit of
₹ 10,147.00 (101.47%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-0.80 (-0.06%)
Day High
₹1,354.80
Day Low
₹1,309.20
Day Open
₹1,350.10
Prev Close
₹1,345.20
Volume
76,178
Value Traded
₹10.16 Cr
1W Return
-2.13%
1M Return
-3.06%
3M Return
15.89%
6M Return
28.50%
1Y Return
43.97%
Market Cap (₹ Cr.)
16,505
PE Ratio
27.40
PB Ratio
4.95
Dividend Yield
0.37%
ROE
16.94%
ROCE
21.78%
Book Value (₹)
271.41
Face Value (₹)
2.00
EPS (TTM)
-
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-2.13%
6 Week
-
1 Month
-3.06%
3 Month
15.89%
9 Month
51.46%
No data available.
Alivus Life Sciences receives ₹25.61 lakh CGST order for FY21-22
Alivus Life Sciences received a CGST order for FY21-22 totaling ₹25.61 lakh in tax. Penalty amount equals the tax demand at ₹25,61,400, plus applicable interest. Order issued under Section 74(1) of CGST Act by Vadodara-II Commissionerate. Company states no material financial or operational impact from the order. Management is assessing options to file an appeal against the ruling.
4 days agoAlivus Life Sciences incorporates wholly owned subsidiary in Brazil
Alivus Life Sciences incorporated wholly owned subsidiary Alivus Life Sciences Do Brasil Ltda in Brazil. Entity registered in Sao Paulo on September 15, 2026 with authorized capital of R$ 500,000. Company holds 100% stake via cash consideration not exceeding R$ 500,000. Transaction approved by Brazilian National Registrar of Legal Entities.
27 days agoAlivus Life Sciences to host investor meet at Kotak Healthcare Forum
Alivus Life Sciences to attend Kotak Healthcare Forum 2026 on September 17, 2026. In-person meetings in Mumbai will include group and one-on-one sessions. Disclosure made under Regulation 30 of SEBI LODR Regulations, 2015.
1mo agoAlivus Life Sciences passes ₹5 dividend, approves FY26 results at AGM
Alivus Life Sciences shareholders approved a final dividend of ₹5 per share for FY26. All four ordinary resolutions, including adoption of financials, passed with requisite majority. Promoter group voted 100% in favor of all agenda items. Reappointment of Chairman Hiren Patel faced minor opposition from public institutions.
1mo agoAlivus Life Sciences to host investor meetings on Sep 9 in Mumbai
Alivus Life Sciences to hold one-on-one meetings with four investors on September 9, 2026. Participants include Breakout Capital, UTI, Kotak Mutual Fund, and Param Capital. All sessions are scheduled as in-person meetings in Mumbai. Disclosure made under Regulation 30 of SEBI LODR Regulations, 2015.
1mo agoAlivus Life Sciences schedules investor meetings with Mirae Asset, Emkay
Alivus Life Sciences schedules investor meetings from August 28 to September 2, 2026. Participants include Mirae Asset (US), Emkay Global, SIMPL, and Lyptus Capital. Meetings are designated as one-on-one sessions. Engagements will be held virtually and in-person in Mumbai.
1mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 5 years ago in Alivus Life Sciences is now worth
₹ 20,147.00
giving a profit of
₹ 10,147.00 (101.47%)
Note: Past profits do not guarantee future returns.
